(Q54068522)

24 May 2018

title

Dose-related effects of GLP-1 on insulin secretion, insulin sensitivity, and glucose effectiveness in mice. (English)

1 reference

24 May 2018

1 reference

1

B Ahrén

1 reference

24 May 2018

author name string

G Pacini

series ordinal

2

1 reference

24 May 2018

language of work or name

English

0 references

publication date

1 December 1999

1 reference

24 May 2018

American Journal of Physiology

published in

1 reference

24 May 2018

volume

277

1 reference

24 May 2018

issue

6 Pt 1

1 reference

24 May 2018

page(s)

E996-E1004

1 reference

24 May 2018

Importance of glucose per se to intravenous glucose tolerance. Comparison of the minimal-model prediction with direct measurements.

cites work

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Lilly lecture 1989. Toward physiological understanding of glucose tolerance. Minimal-model approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Role of glucose effectiveness in the determination of glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Glucagon-like peptide 1 enhances glucose tolerance both by stimulation of insulin release and by increasing insulin-independent glucose disposal

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Elimination of the action of glucagon-like peptide 1 causes an impairment of glucose tolerance after nutrient ingestion by healthy baboons

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Potential therapeutic levels of glucagon-like peptide I achieved in humans by a buccal tablet

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

GLP-1 tablet in type 2 diabetes in fasting and postprandial conditions

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Pancreatic beta-cells are rendered glucose-competent by the insulinotropic hormone glucagon-like peptide-1(7-37).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

The antidiabetogenic effect of GLP-1 is maintained during a 7-day treatment period and improves diabetic dyslipoproteinemia in NIDDM patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

The interaction between the adenylate cyclase system and insulin-stimulated glucose transport. Evidence for the importance of both cyclic-AMP-dependent and -independent mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Infusion of insulin impairs human adipocyte glucose metabolism in vitro without decreasing adipocyte insulin receptor binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Metabolic consequences of prolonged hyperinsulinemia in humans. Evidence for induction of insulin insensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Glucagon-like peptide 1 (GLP-1) as a new therapeutic approach for type 2-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Method of insulin administration has no effect on insulin sensitivity estimates from the insulin-modified minimal model protocol

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Exendin(9-39)amide is an antagonist of glucagon-like peptide-1(7-36)amide in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Glucagon-like peptide 1: a potent glycogenic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Effect of glucagon-like peptide-1 (proglucagon 78-107amide) on hepatic glucose production in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

Glucagon-like peptide-1 reduces hepatic glucose production indirectly through insulin and glucagon in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

GLP-1 does not acutely affect insulin sensitivity in healthy man

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPENDO.1999.277.6.E996

10.1152/AJPENDO.1999.277.6.E996

21 January 2018

Identifiers

DOI

0 references

PubMed ID

10600787

1 reference

24 May 2018